Real‐world titration, persistence & weight loss of semaglutide and tirzepatide in an academic obesity clinic
GLP1RA persistence and dosetitration adherence were moderate but weight loss approximated that seen in clinical trials, supporting real-world effectiveness.
Authors
- Matthew D. Spann (ORCID: https://orcid.org/0000-0001-9228-6656)
- Heidi J. Silver (ORCID: https://orcid.org/0000-0003-2237-4903)
- Rebecca Irlmeier (ORCID: https://orcid.org/0000-0001-8210-9584)
- Jason M. Samuels (ORCID: https://orcid.org/0000-0001-5427-3117)
- Gitanjali Srivastava (ORCID: https://orcid.org/0000-0002-8326-3089)
- Fei Ye (ORCID: https://orcid.org/0000-0001-6472-5076)
Institutions
- Vanderbilt University (US)
- VA Tennessee Valley Healthcare System (US)
- Sylvester Comprehensive Cancer Center (US)
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-08-05
- DOI
- https://doi.org/10.1111/dom.70004
- Citations
- 9
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 11.65
Funders
- National Center for Advancing Translational Sciences